Thalia Therapeutics raises $3.3M (United Kingdom, Jun 2026)
$3.3M
€3.1 MillionGenerated social card
Headline
Thalia Therapeutics Secures €3.1 Million and Acquires Sanmi - n24.com.tr
About
Thalia Therapeutics is a UK-based biotechnology company specializing in RNA-based medical solutions. The company has raised €3.1 million to accelerate its clinical-stage oncology and RNA-based pipeline, including the acquisition of Sanmirna Therapeutics, which brings a microRNA therapeutic candidate into its portfolio.
Article summary
Thalia Therapeutics Secures €3.1 Million and Acquires Sanmi n24.com.tr
Founder
Dr. David Solomon
CEO
Investors · 1
Premier MitonLead
FUND
Related rounds
| Aug 12, 2026 | Cytix | $6.4M | Series A | United Kingdom |
| Aug 12, 2026 | Pyra | $200.0M | — | United Kingdom |
| Aug 10, 2026 | — | — | United Kingdom | |
| Aug 10, 2026 | Cambridge Aerospace | $300.0M | — | United Kingdom |